Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | ROCK2 | O75116 | 12/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 6/20 | 0.43 |
| ▸ | CDC42BPA | Q5VT25 | 1/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.42 |
| ▸ | DHODH | Q02127 | 1/20 | 0.41 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.40 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21359390 | 0.88 | MIF (0.51) | MIFKDM4EPOLBROCK2ROCK1 | |
| SCHEMBL22861266 | 0.88 | ROCK2 (0.48) | ROCK2ROCK1CDC42BPA | |
| SCHEMBL21359432 | 0.87 | PTPN11 (0.47) | MIFKDM4EPOLBROCK2ROCK1 | |
| SCHEMBL21359486 | 0.87 | MIF (0.51) | MIFROCK2ROCK1LRRK2DHODH | |
| SCHEMBL21359530 | 0.86 | XDH (0.51) | MIFKDM4EPOLBROCK2ROCK1 | |
| SCHEMBL21359482 | 0.86 | XDH (0.51) | MIFKDM4EPOLBROCK2ROCK1 | |
| SCHEMBL21359438 | 0.86 | KDM4E (0.64) | KDM4EPOLBROCK2ROCK1 | |
| SCHEMBL21359555 | 0.83 | PLAU (0.51) | MIFKDM4EPOLBROCK2ROCK1 | |
| SCHEMBL21359523 | 0.82 | MIF (0.66) | MIFKDM4EPOLBROCK2ROCK1 | |
| SCHEMBL21359480 | 0.80 | KDM4E (0.51) | MIFKDM4EPOLBROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230057076-A1 | Pyrazole-Containing Macrophage Migration Inhibitory Factor Inhibitors | UNIV YALE (US) | 2023-02-23 | — | — | US | disclosed |
| US-20210002264-A1 | Pyrazole-Containing Macrophage Migration Inhibitory Factor Inhibitors | UNIV YALE (US) | 2021-01-07 | — | — | US | disclosed |
| WO-2019178480-A1 | PYRAZOLE-CONTAINING MACROPHAGE MIGRATION INHIBITORY FACTOR INHIBITORS | YALE UNIVERSITY (US) | 2019-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210002264-A1 | Pyrazole-Containing Macrophage Migration Inhibitory Factor Inhibitors | MIF, MMP12, CSF1R | MIF 1/4885KDM4E 1211/4885POLB 4740/4885 |
| US-20230057076-A1 | Pyrazole-Containing Macrophage Migration Inhibitory Factor Inhibitors | MIF, MMP12, CSF1R | MIF 1/4885KDM4E 1525/4885POLB 4781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.